Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Recruiting 454Active not recruiting 374Completed 244Terminated 111Not yet recruiting 52Withdrawn 19Suspended 5Enrolling by invitation 2Temporarily not available 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Lung Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Lymphoma 1Histiocytic Sarcoma 1Head and Neck Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Dendritic Cell Sarcoma, Follicular 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 11venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Etoposide 5Cisplatin 5Bevacizumab 5fludarabine phosphate 4fludarabine 4Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Radiation 4Doxorubicin 4Cetuximab 4durvalumab 3decitabine and cedazuridine drug combination 3X-Rays 3Tacrolimus 3Surveys and Questionnaires 3Prednisone 3Platinum 3Leucovorin 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Suspended × pembrolizumab × 1 year × Clear all
NCT04266730 2026-04-23

PANDA-VAC

UNC Lineberger Comprehensive Cancer Center

Phase 1 Suspended
6 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms

NCT06219174 2026-03-06

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Suspended
45 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06860386 2026-03-06

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Suspended
75 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

NCT03384836 2025-07-02

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Roswell Park Cancer Institute

Phase 1/2 Suspended
47 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡